Home > Boards > US Listed > Biotechs > Anavex Life Sciences Corp (AVXL)

re: "He had similar expression for PRANA drug

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
apostrophe Member Profile
 
Followed By 19
Posts 1,084
Boards Moderated 0
Alias Born 10/17/06
160x600 placeholder
Anavex Life Sciences to Present at the 4th Annual Evercore ISI HealthCONx Conference GlobeNewswire Inc. - 11/29/2021 7:00:00 AM
Anavex Life provides key updates on clinical trials in rare genetic neurological disorders Seeking Alpha - 11/24/2021 9:40:36 AM
Anavex Life Sciences EPS misses by $0.39 Seeking Alpha - 11/24/2021 7:07:01 AM
Anavex Life Sciences Provides Business Update and Reports Fiscal 2021 Year End Financial Results GlobeNewswire Inc. - 11/24/2021 7:00:00 AM
Notable earnings after Wednesday's close Seeking Alpha - 11/23/2021 5:35:23 PM
Anavex Life Sciences FY 2021 Earnings Preview Seeking Alpha - 11/23/2021 1:20:23 PM
Notable earnings before Wednesday's open Seeking Alpha - 11/23/2021 10:42:34 AM
Anavex Life Sciences to Announce Fiscal 2021 Year End Financial Results on Wednesday, November 24, 2021 GlobeNewswire Inc. - 11/17/2021 7:00:00 AM
Anavex Life Sciences Announces Participation at Upcoming Lausanne VIII Workshop Panel - Building Global Momentum for Interventions in Alzheimer’s Disease GlobeNewswire Inc. - 11/10/2021 7:00:00 AM
Anavex Life Sciences to Present at the Dawson James Securities 6th Annual Conference GlobeNewswire Inc. - 10/15/2021 7:00:00 AM
Anavex Life Sciences Reports Data Review by the Independent Data Safety Monitoring Board for its Phase 2b/3 Clinical Trial of ANAVEX®2-73 in Patients with Alzheimer’s Disease GlobeNewswire Inc. - 10/13/2021 7:00:00 AM
Cassava down after phase 3 simufilam announcement; other Alzheimer's names follow Seeking Alpha - 10/6/2021 12:51:22 PM
CEO Presenting on the Emerging Growth Conference on September 29  Register Now InvestorsHub NewsWire - 9/28/2021 8:00:00 AM
Anavex Life Sciences Announces Participation at 5th Pharma Pricing, Reimbursement & Market Access 2021 GlobeNewswire Inc. - 9/27/2021 9:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/27/2021 8:11:01 AM
Anavex Life Sciences Announces Uplisting to the NASDAQ Global Select Market® GlobeNewswire Inc. - 9/27/2021 7:00:00 AM
Automatic Shelf Registration Statement of Securities of Well-known Seasoned Issuers (s-3asr) Edgar (US Regulatory) - 9/24/2021 5:05:26 PM
Anavex Life Sciences to Present at the 2021 Cantor Virtual Global Healthcare Conference GlobeNewswire Inc. - 9/20/2021 7:00:00 AM
CEO Presenting on the Emerging Growth Conference Today!  Register Now InvestorsHub NewsWire - 9/15/2021 7:00:00 AM
Anavex Life Sciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference GlobeNewswire Inc. - 9/9/2021 7:00:00 AM
CEO Presenting on the Emerging Growth Conference Today.  Register Now InvestorsHub NewsWire - 9/1/2021 7:00:00 AM
Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Autism) GlobeNewswire Inc. - 8/26/2021 7:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/12/2021 5:13:54 PM
Anavex Life Sciences Provides Business Update and Reports Fiscal 2021 Third Quarter Financial Results GlobeNewswire Inc. - 8/12/2021 7:00:00 AM
Anavex Life Sciences to Announce Fiscal 2021 Third Quarter Financial Results on Thursday, August 12, 2021 GlobeNewswire Inc. - 8/5/2021 7:00:00 AM
apostrophe   Tuesday, 09/19/17 10:30:41 PM
Re: XenaLives post# 120730
Post # of 338768 
re: "He had similar expression for PRANA drug and trial. So not very reliable "

re:"That's not what I remember - can you back your claim up with the EXACT quote about PRANA, including how many people he was talking about?

We may recall an article from 2013

"Macfarlane said that the drug seems to have slowed the progression of the disease by about 30 percent in patients with mild Alzheimer’s compared to placebo"

MacPharlane's also makes a more upbeat remark was about a single patient out of the whole group who managed to show some improvement as a "preliminary response" . This is what certain people seem to remember while forgetting about his objective factual account quoted above describing mediocre (ie not very good) PRANA results overall, in the same article.

Macpharlane is reliable. Just how the press chooses to adjust emphasis in a story for maximum public readership appeal is sometimes unreliable in regard to presenting reality. Will they write: "Ten million people bought lottery tickets but didn't win." or "Poor man wins fortune!".

"The article indirectly references Prana’s oral drug, called PBT2, and the IMAGINE trial, discussing the benefits that have been observed in a 57-year-old Alzheimer’s patient named Kelvin Lawler.

Further, Prana was pegged to the article with an image of its experimental 250 mg red pill and pill bottle with the name of the drug used in the accompanying video.

According to Associate professor Steve Macfarlane, who has been overseeing the trial at Melbourne’s Caulfield Hospital as part of the global study, the preliminary response by Lawler has been “incredible.” Macfarlane noted a clear improvement in Lawler’s memory, saying Lawler is a “poster child for success in clinical trials.”

The IMAGINE trial is a 12-month, double-blind study where patients are administered PBT2 once per day and tested once per month for any effect."

https://www.equities.com/news/prana-biotechnology-pran-continues-upward-on-alzheimer-s-disease-drug-news

There is no comparison, no parallel in past trials to what we are seeing now in regard to good results with Anavex 2-73



Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences